Sign in or create an account to add this stock to your watchlist.
About ArthroCare (NASDAQ:ARTC)
ArthroCare Corporation (ArthroCare) is a medical device company. ArthroCare develops and manufactures surgical devices, instruments, and implants. Its devices enable surgical procedures and enable new minimally invasive procedures. Many of ArthroCare's devices use its Coblation technology. This technology dissolves target tissue and limits damage to surrounding healthy tissue. ArthroCare also develops surgical devices utilizing other patented technology, including its OPUS line of fixation products, as well as re-usable surgical instruments. ArthroCare's two core product consists of sports medicine and ear, nose, and throat (ENT), as well as other areas, such as spine, wound care, urology and gynecology. It's Sports Medicine, ENT and other products are marketed and sold through two principal geographic distribution channels: Americas (North and South America) and International (all other geographies). In May 2014, Smith & Nephew PLC acquired the Company.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
SymbolNASDAQ:ARTC
CUSIP04313610
Phone+1-512-3913900
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
ArthroCare (NASDAQ:ARTC) Frequently Asked Questions
What is ArthroCare's stock symbol?
ArthroCare trades on the NASDAQ under the ticker symbol "ARTC."
Who are ArthroCare's key executives?
ArthroCare's management team includes the folowing people:
- Gayle Wiley, Chief Human Resource Officer, Senior Vice President
- Jean A. Woloszko M.D., Ph.D., Senior Vice President - Research and Development, Chief Technology Officer (Age 56)
- Richard W. Rew II, Senior Vice President, General Counsel, Secretary (Age 49)
- Scott Schaffner, Senior Vice President, General Manager - Sports Medicine (Age 44)
- Fred B. Dinger III, Senior Vice President, General Manager of ENT
- James L. Pacek, Senior Vice President - Global Markets and Sales Operations (Age 65)
- Bruce C. Prothro, Chief Regulatory Officer, Senior Vice President - Quality Systems and Assurance (Age 52)
- Fabiana Lacerca-Allen, Independent Director (Age 47)
Has ArthroCare been receiving favorable news coverage?
Media coverage about ARTC stock has been trending positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ArthroCare earned a news sentiment score of 0.29 on Accern's scale. They also gave media coverage about the medical device company an impact score of 47.04 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of ArthroCare?
Shares of ARTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact ArthroCare?
ArthroCare's mailing address is 7000 W William Cannon Dr, AUSTIN, TX 78735-8509, United States. The medical device company can be reached via phone at +1-512-3913900.
MarketBeat Community Rating for ArthroCare (ARTC)
MarketBeat's community ratings are surveys of what our community members think about ArthroCare and other stocks. Vote "Outperform" if you believe ARTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
ArthroCare (NASDAQ:ARTC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for ArthroCare in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
ArthroCare (NASDAQ:ARTC) Consensus Price Target History
ArthroCare (NASDAQ:ARTC) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 1/22/2018 | Chardan Capital | Initiated Coverage | Buy | | Low |  |
(Data available from 5/24/2016 forward)
ArthroCare (NASDAQ:ARTC) Earnings History and Estimates Chart
ArthroCare (NASDAQ ARTC) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/2/2014 | Q313 | $0.35 | $0.32 | $96.00 million | $96.06 million | View | N/A | |
| 2/13/2014 | Q213 | $0.40 | $0.30 | $100.53 million | $101.70 million | View | N/A | |
| 10/29/2013 | Q3 2013 | $0.29 | $0.27 | $89.46 million | $91.86 million | View | N/A | |
| 8/5/2013 | Q2 2013 | $0.34 | ($0.27) | $93.67 million | $92.10 million | View | Listen | |
| 5/7/2013 | Q1 2013 | $0.37 | $0.30 | $94.41 million | $92.30 million | View | Listen | |
| 2/13/2013 | Q4 2012 | $0.37 | $0.30 | $93.78 million | $96.90 million | View | Listen | |
| 10/31/2012 | | $0.28 | $0.27 | | | View | N/A | |
| 8/1/2012 | | $0.37 | $0.34 | | | View | N/A | |
| 5/2/2012 | | $0.34 | $0.36 | | | View | N/A | |
| 2/16/2012 | | $0.41 | ($1.06) | | | View | N/A | |
| 11/2/2011 | | $0.30 | $0.05 | | | View | N/A | |
| 8/3/2011 | | $0.35 | $0.34 | | | View | N/A | |
| 5/2/2011 | | $0.30 | $0.36 | | | View | N/A | |
| 2/14/2011 | | $0.28 | $0.30 | | | View | N/A | |
| 11/1/2010 | Q3 2010 | $0.19 | $0.25 | | | View | N/A | |
| 8/3/2010 | Q2 2010 | $0.19 | $0.22 | | | View | N/A | |
| 5/5/2010 | Q1 2010 | $0.13 | $0.24 | | | View | N/A | |
| 3/15/2010 | Q4 2009 | ($0.08) | $0.21 | | | View | N/A | |
| 11/18/2009 | Q4 2008 | | ($0.35) | | | View | N/A | |
| 4/21/2008 | Q1 2008 | $0.32 | $0.34 | | | View | N/A | |
| 2/19/2008 | Q4 2007 | $0.49 | $0.50 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
ArthroCare (NASDAQ:ARTC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ArthroCare (NASDAQ ARTC) Insider Trading and Institutional Ownership History
ArthroCare (NASDAQ ARTC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/9/2014 | Jean Woloszko | SVP | Sell | 32,627 | $45.67 | $1,490,075.09 | 40,511 | |
| 1/8/2014 | Barbara Boyan | Director | Sell | 10,000 | $45.00 | $450,000.00 | 24,525 | |
| 1/8/2014 | Bruce Prothro | SVP | Sell | 33,478 | $45.82 | $1,533,961.96 | 39,421 | |
| 1/6/2014 | Bruce Prothro | SVP | Sell | 6,167 | $39.75 | $245,138.25 | 39,421 | |
| 12/19/2013 | Barbara Boyan | Director | Sell | 10,000 | $40.00 | $400,000.00 | 24,525 | |
| 12/19/2013 | Jean Woloszko | SVP | Sell | 10,657 | $39.98 | $426,066.86 | 46,193 | |
| 10/30/2013 | Jean Woloszko | SVP | Sell | 1,342 | $37.95 | $50,928.90 | | |
| 10/7/2013 | James Pacek | SVP | Sell | 2,500 | $34.48 | $86,200.00 | 24,379 | |
| 6/18/2013 | Bruce Prothro | SVP | Sell | 2,512 | $36.00 | $90,432.00 | | |
| 5/24/2013 | Peter Wilson | Director | Sell | 10,000 | $33.36 | $333,600.00 | | |
| 11/13/2012 | David Fitzgerald | Director | Sell | 25,000 | $31.34 | $783,500.00 | | |
| 8/7/2012 | James G Foster | Director | Sell | 35,000 | $28.81 | $1,008,350.00 | | |
(Data available from 1/1/2013 forward)
ArthroCare (NASDAQ ARTC) News Headlines
| Source: |
|
ArthroCare (NASDAQ:ARTC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ArthroCare (NASDAQ:ARTC) Income Statement, Balance Sheet and Cash Flow Statement
ArthroCare (NASDAQ ARTC) Stock Chart for Thursday, May, 24, 2018
Loading chart…
